Literature DB >> 30069245

A Rare Case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Glimepiride, the Unlikely Culprit.

Nishanth Dev1.   

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare and challenging entity which can be life threatening and is associated with many medications. Yet, Glimepiride has never been reported as offending agent. We present here the first case of Glimepiride induced DRESS syndrome. A 40-year-old male with type 2 diabetes mellitus was prescribed Glimepiride. One month later, the patient presented with diffuse rash, fever, swelling of extremities and jaundice. The leucocyte count at presentation was 22,000 cells/microL and absolute eosinophil count 5,400 cells/microL, with no atypical cells on peripheral blood smear. Skin biopsy was non-specific. Other sources of infections such as parasitic infections, HIV, viral hepatitis were ruled out. Patient improved symptomatically on discontinuation of Glimepiride and improved dramatically on steroids. DRESS syndrome as a possible complication of Glimepiride should be considered by clinicians. According to RegiSCAR, our case was categorized as definitive with score of 7. In the vast majority of reported cases, they are classified as probable cases.

Entities:  

Year:  2018        PMID: 30069245      PMCID: PMC6060300          DOI: 10.26574/maedica.2018.13.2.155

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  11 in total

1.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Authors:  Sonal Choudhary; Michael McLeod; Daniele Torchia; Paolo Romanelli
Journal:  J Clin Aesthet Dermatol       Date:  2013-06

2.  Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?

Authors:  S H Kardaun; A Sidoroff; L Valeyrie-Allanore; S Halevy; B B Davidovici; M Mockenhaupt; J C Roujeau
Journal:  Br J Dermatol       Date:  2007-03       Impact factor: 9.302

3.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.

Authors:  B Rzany; O Correia; J P Kelly; L Naldi; A Auquier; R Stern
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

Review 4.  Severe adverse cutaneous reactions to drugs.

Authors:  J C Roujeau; R S Stern
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

5.  Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response.

Authors:  Damien Picard; Baptiste Janela; Vincent Descamps; Michel D'Incan; Philippe Courville; Serge Jacquot; Sylvie Rogez; Laurent Mardivirin; Hélène Moins-Teisserenc; Antoine Toubert; Jacques Benichou; Pascal Joly; Philippe Musette
Journal:  Sci Transl Med       Date:  2010-08-25       Impact factor: 17.956

Review 6.  Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).

Authors:  H Bocquet; M Bagot; J C Roujeau
Journal:  Semin Cutan Med Surg       Date:  1996-12

Review 7.  The DRESS syndrome: a literature review.

Authors:  Patrice Cacoub; Philippe Musette; Vincent Descamps; Olivier Meyer; Chris Speirs; Laetitia Finzi; Jean Claude Roujeau
Journal:  Am J Med       Date:  2011-05-17       Impact factor: 4.965

8.  Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases.

Authors:  Yi-Chun Chen; Hsien-Ching Chiu; Chia-Yu Chu
Journal:  Arch Dermatol       Date:  2010-08-16

Review 9.  Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update.

Authors:  S Tas; T Simonart
Journal:  Dermatology       Date:  2003       Impact factor: 5.366

10.  A 6-month prospective survey of cutaneous drug reactions in a hospital setting.

Authors:  F Fiszenson-Albala; V Auzerie; E Mahe; R Farinotti; C Durand-Stocco; B Crickx; V Descamps
Journal:  Br J Dermatol       Date:  2003-11       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.